Chitosan-pentaglycine-phenylboronic acid conjugate: A potential colon-specific platform for calcitonin

Bioconjugate Chemistry

Volumn 17, Issue 4, 2006, Pages 1000-1007

  Smoum, Reem ^a   Rubinstein, Abraham ^a,b   Srebnik, Morris ^a,b  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b NONE   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CHITOSAN; DEGRADATION; DRUG DELIVERY;

ACID PROTEASE; BORONIC ACID; CHITOSANASE; DRUG DELIVERY VEHICLES; INHIBITORY EFFECT; MUCOADHESIVES; PHENYLBORONIC ACIDS; POLYSACCHARIDE CHITOSAN; PROTEASE INHIBITOR; SALMON CALCITONIN;

ENZYME INHIBITION;

4 FORMYLPHENYLBORONIC ACID; BENZENEBORONIC ACID; CHITOSAN; CHITOSANASE; ELASTASE; GLYCINE DERIVATIVE; GLYCYLGLYCINE; PENTAGLYCINE; POLYSACCHARIDE; PROTEINASE INHIBITOR; SALCATONIN; SERINE PROTEINASE; TRYPSIN; UNCLASSIFIED DRUG;

ARTICLE; BIODEGRADABILITY; COVALENT BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; ENZYME INHIBITION; PROTEIN DEGRADATION;

EID: 33746671262     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc050357y     Document Type: Article

References (30)

1. Bai, J. P., Chang, L. L., and Guo, J. H. (1995) Targeting of peptide and protein drugs to specific sites in the oral route. Crit. Rev. Ther. Drug Carrier Syst. 12, 339-371.
2. Lee, H. J. (2002) Protein drug oral delivery: the recent progress. Arch. Pharm. Res. 25, 572-584.
3. Shah, R. B., Ahsan, F., and Khan, M. A. (2002) Oral delivery of proteins: progress and prognostication. Crit. Rev. Ther. Drug Carrier Syst. 19, 135-169.
4. Sintov, A., Simberg, M., and Rubinstein, A. (1996) Absorption enhancement of captopril in the rat colon as a putative method for captopril delivery by extended release formulations. Int. J. Pharm. 143, 101-106.
5. Haupt, S., and Rubinstein A. (2002) The colon as a possible target for orally administered peptide and protein drugs. Crit. Rev. Ther. Drug Carrier Syst. 19, 499-545.
6. Phillips, S. F., Pemberton, J. H., and Shorter, R. G. (1991) The Large Intestine: Physiology, Pathophysiology, and Disease, Raven Press, New York.
7. Baluom, M., Friedman, M., and Rubinstein, A. (1998) The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. Int. J. Pharm. 176, 21-30.
8. Bernkop-Schnürch, A., and Kast, C. E. (2001) Chemically modified chitosans as enzyme inhibitors. Adv. Drug Delivery Rev. 52, 127-137.
9. Matthews, D. A., Alden, R. A., Birktoft, J. J, Freer, S. T., and Kraut, J. (1975) X-ray crystallographic study of boronic acid adducts with subtilisin BPN' (Novo). A model for the catalytic transition state. J. Biol. Chem. 250, 7120-7126.
10. Kettner, C. A., and Shenvi, A. B. (1984) Inhibition of the serine proteases leukocyte elastase, pancreatic elastase, cathepsin G, and chymotrypsin by peptide boronic acids. J. Biol. Chem. 259, 15106-15114.
11. Rubinstein, A. (2005) Colonic drug delivery. Drug Discovery Today Technol. 2, 33-37.
12. Rubinstein, A. (2000) Natural polysaccharides as targeting tools of drugs to the human colon. Drug Dev. Res. 50, 435-439.
13. Ravi Kumar, M. N. V., Muzzarelli, R. A. A., Muzzarelli, C., Sashiwa, H., and Domb, A. J. (2004) Chitosan chemistry and pharmaceutical perspectives. Chem. Rev. 104, 6017-6084.
14. Tozaki, H., Odoriba, T., Okada, N., Fujita, T., Terabe, A., Suzuki, T., Okabe, S., Muranishi, S., and Yamamoto, A. (2002) Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J. Controlled Release 82, 51-61.
15. Azria, M. (1989) in The Calcitonins: Physiology and Pharmacology (Azria, M., Ed.), Karger, Basel, Switzerland.
16. Morimoto, K., Katsumata, H., Yabuta, T., Iwanaga, K., Kakemi, M., Tabata, Y., and Ikada, Y. (2001) Evaluation of gelatin microspheres for nasal and intramuscular administrations of salmon calcitonin. Eur. J. Pharm. Sci. 13, 179-185.
17. Omura, Y., Renbutsu E., Morimoto M., Saimoto H., and Shigemasa Y. (2003) Synthesis of new chitosan derivatives and combination with biodegradable polymer. Polym. Adv. Technol. 14, 35-39.
18. Fukamizo, T., Honda, Y., Goto, S., Boucher, I., and Brzezinski, R. (1995) Reaction mechanism of chitosanase from Streptomyces sp. N174. Biochem. J. 311, 377-383.
19. Lehr, C.-M., Bouwstra, J. A., Schacht, E. H., and Junginger, H. E. (1992) In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78, 43-48.
20. Ranaldi, G., Marigliano, I., Vespignani, I., Perozzi, G., and Sambuy, Y. (2002) The effect of chitosan and other polycations on tight junction permeability in the human intestinal Caco-2 cell line. J. Nutr. Biochem. 13, 157-167.
21. Bernkop-Schnürch, A., Bratengeyer, I., and Valenta, C. (1997) Development and in vitro evaluation of a drug delivery system protecting from trypsinic degradation. Int. J. Pharm. 157, 17-25.
22. Lehr, C.-M. (1994) Bioadhesion Technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug 11, 119-160.
23. Bernkop-Schnürch, A. (2000) Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 194, 1-13.
24. Bernkop-Schnürch, A., and Scerbe-Saiko, A. (1998) Synthesis and in vitro evaluation of chitosan-EDTA-Protease-Inhibitor conjugates which might be useful in oral delivery of peptides and proteins. Pharm. Res. 15, 263-269.
25. Bernkop-Schnürch, A., Schwarz, G. H., and Kratzel, M. (1997) Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. J. Controlled Release 47, 113-121.
26. Marschütz, M. K., Veronese, F. M., and Bernkop-Schnürch, A. (2001) Influence of the spacer on the inhibitory effect of different polycarbophil-protease inhibitor conjugates. Eur. J. Pharm. Biopharm. 52, 137-144.
27. Sakuma, S. Ishida, Y., Sudo, R., Suzuki, N., Kikuchi, H., Hitawari, K., Kishida, A., Akashi, M., and Hayashi, M. (1997) Stabilization of salmon calcitonin by poly(styrene) nanoparticles having surface hydrophilic polymeric chains against enzymatic degradation. Int. J. Pharm. 159, 181-189.
28. Guggi, D., and Bernkop-Schnürch A. (2003) In vitro evaluation of polymeric excipients protecting calcitonin against degradation by intestinal serine proteases. Int. J. Pharm. 252, 187-196.
29. Takeuchi, H., Yamamoto, H., and Kawashima, Y. (2001) Muco-adhesive nanoparticulate systems for peptide drug delivery. Adv. Drug Delivery Rev. 47, 39-54.
30. Marschütz, M. A., Caliceti, P., and Bernkop-Schnürch, A. (2000) Design and in vivo evaluation of the oral delivery system of an oral delivery system for insulin. Pharm. Res. 17, 1468-1474.